As compared with the HER2-high group, both the HER2-zero and the HER2-low group had less tumor with perineural invasion (14.3% vs. 31.6%, p = 0.001 and 13.1% vs. 31.6%, p < 0.001) and less stage III disease (41.8% vs. 56.1%, p = 0.044 and 39.9% vs. 56.1%, p = 0.022) (Table 1 and Figure 3a,b). This evidence concerns the gene ERBB2 and neoplasm.